Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • NITI Aayog asked to...

    NITI Aayog asked to revamp process of drug selection for price control

    Written by Ruby Khatun Khatun Published On 2018-01-15T16:19:08+05:30  |  Updated On 15 Jan 2018 4:19 PM IST
    NITI Aayog asked to revamp process of drug selection for price control

    New Delhi: The system of selections of drugs for Price Control may now undergo a sea change as the government has asked the NITI Aayog to revamp the current system of price fixation in consultation pharma lobby groups


    Recent media articles report that this comes after the Prime Minister’s Office (PMO) asked NITI Aayog to interfere and address the dissatisfaction of the industry bodies over the proposed pharmaceuticals policy and price control


    The pharma groups have also shown their worry over the current way of fixing price caps by National Pharmaceutical Pricing Authority (NPPA).


    In the present scenario, the list of drugs suitable for price regulation is prepared by the health ministry after that the Department of Pharmaceuticals (DoP) incorporates the National List of Essential Medicines (NLEM) into Schedule 1 of the Drugs (Prices Control) Order (DPCO). Subsequently, the NPPA fixes the prices of drugs in this schedule.


    Thereafter, NLEM listed drugs and devices must be sold at the price fixed by NPPA while non-scheduled listed drugs are permitted to have a maximum annual price hike of 10%. Around 750 formulations are currently present in India’s list of essential medicines.


    According to Mint, the PMO has asked Niti Aayog to prepare a roadmap to revamp the process of drug selection for price control and submit a report to the PMO based on their consultations with the pharma lobby groups and pharma experts.


    In its meeting with pharma sector experts, NITI Aayog officials had asked them to share their views on NLEM, whether it should be linked to DPCO, which drugs they think should come under price control, whether there is any need to amend the DPCO, how they think price caps should be determined and whether they agree with the current method.


    The pharma lobby was also asked to propose changes in the manner the government identifies medicines that should be brought under price control and what they feel is the best approach to have timely additions and deletions in NLEM. Besides this companies were asked to share their views about the maximum allowable trade margins on ex-factory price.


    Speaking with Mint a person knowing about the matter said, “Price control has been an area of concern not only for the pharmaceutical industry but also for the NPPA, which is the price governing body. Various efforts have been made to get the correct balance between the interests of the consumers and pharmaceutical industry but to no avail. Niti Aayog has been told to bridge that balance and look at the concerns of both consumers and pharma lobby groups.”

    Department of PharmaceuticalsDOPDrugs Prices Control OrderHealth MinistryNational List of Essential MedicinesNational Pharmaceutical Pricing AuthorityNiti AayogNLEMNPPApharma lobby groupsPMOprice capsPrice ControlPrime Ministers officeprocess of drug selectionproposed pharmaceuticals policyrevamp
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok